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The anticancer potential by breastfeeding is not fully tapped in the light of the present
knowledge of the subject. Literature indicates that breastmilk has anticancer action but
may underestimate its full capacity. The protective spectrum within breastmilk hints on
the need for a more comprehensive understanding of it as an anticancer tool. Exclusive
breastfeeding could confer protection from carcinogenesis with a greater impact than
realised. A literature review was conducted using four electronic databases. Selected areas
were extracted after thorough perusal of the articles. The uninitiated would take exclusive
breastfeeding seriously if actively counselled as an anticancer tool. Advice on details of
the breastfeeding process and holistic information on breastfeeding may endow a greater
impact among the skeptics. Counselling the breastfeeding mother on information
sometimes not imparted, such as on maternal nutrition, details of the process of breast-
feeding, beneﬁts of direct breastfeeding versus milk expression and her psychosocial well
being may make a difference in optimising anticancer action that exists in breastmilk.
Additionally, its anticancer potential provides a platform to universally improve physical
and psychosocial well being of women who breastfeed. Statistics of protection by
breastfeeding in some maternal and childhood cancers are evident. “Bio-geno-immuno-
nutrition” of breastmilk may shield the mother and infant from carcinogenesis in more
ways than appreciated. The molecular basis of mother-to-infant signals and their “en-
ergies” need to be researched. Breastfeeding as a modiﬁable behaviour provides cost
effective nutrition with potential for both cancer immunoprophylaxis and
immunotherapy.1. Introduction
The protective potentials within the lactating mammary gland
against cancers are known [1–3]. Despite some statistical support,
the actual numbers of children protected from cancers by
breastfeeding may never be fully appreciated or appraised as
many more children destined to enjoy such protection die of
other causes; infections, being the commonest cause of
childhood mortality [4]. This article reviews some statistics of
breastfeeding protection from cancers for the breastfeeding
mother and child, discusses the multifactorial causes ofcancers and, based on these causes, reﬂects on the potentials
within breastmilk that protect from the aetiopathogenesis of
carcinogenesis.
2. Statistical relevance of breastfeeding and cancer
protection in mother and child
Statistics indicate some level of protection by breastfeeding
against cancers for the mother and infant [1–3]. For the mother,
cohort studies suggest that each month of breastfeeding
reduces the relative risk of ovarian cancers by 2% [relative
risk = 0.98 per month, 95% conﬁdence interval (CI) 0.97–
1.00] [1]. Breastfeeding was found to have a signiﬁcant role in
reducing breast cancer, whereby activities to promote
breastfeeding by information, education, and communication
to inculcate awareness about breast cancer have been
recommended [2]. In women who carried the BRCA1 mutation,
those who breastfed for at least one year had a 32% reductions article under the CC BY-NC-ND license (http://
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0.91, P = 0.008]; breastfeeding for two or more years
conferred a greater risk reduction (OR = 0.51, 95% CI 0.35–
0.74) [5]. Among BRCA2 mutation carriers, no noted link was
found between at least a year's breastfeeding and breast cancer
risk (OR = 0.83, 95% CI 0.53–1.31, P = 0.43) [5]. The effect
of parity on a woman's long-term risk of breast cancer is
modiﬁed by age at ﬁrst full-term pregnancy and possibly by
breastfeeding [6]. Protection against aggressive basal breast
carcinomas as opposed to intraluminal tumours was seen in
women who breastfed [7]. For children, ever having breastfed
were associated with a 21% reduction in risk of childhood
acute leukaemias (OR for all types combined = 0.79, 95% CI
0.70–0.91) [8]. In the commonest childhood tumours,
breastfeeding and delayed introduction of artiﬁcial formula
reduce the risk of acute lymphoblastic leukaemias but not
childhood brain tumours [9]. According to a meta-analysis,
compared with no or shorter breastfeeding, any breastfeeding
for 6 months or longer had a 19% lower risk for childhood
leukaemia (OR = 0.81, 95% CI 0.73–0.89) [3]. Two meta-
analyses found a 1.3-fold higher risk of acute lymphoblastic
leukaemias (95% CI 1.1–1.4) among formula-fed children
compared with children who were breastfed for less than 6
months [10,11], and a 1.2-fold higher risk of acute myeloid
leukaemia (95% CI 1.0–1.4) in formula-fed infants compared
to infants breastfed for more than 6 months [10]. Another
meta-analysis indicated that ever breastfed compared with
never breastfed had a 11% lower risk for childhood leukaemia
(OR = 0.89, 95% CI 0.84–0.94) [3].
3. Multifactorial causes of cancer
The multifactorial aetiologies and time sequence of carcino-
genesis are not entirely known. Microbial homeostasis, immu-
nocompetence, intact gut mucosae and regulated inﬂammation
protect from carcinogenesis [12].
Over 20% of malignancies worldwide are attributed to in-
fectious agents [13]. Viruses by direct expression of viral
oncogenes, can cause cancer, or exert indirect effects by
persistent inﬂammation [13].
Virchow postulated carcinogenesis as an infection related
consequence of loss of epithelial integrity and proinﬂammatory
processes [14]. Bacterial and parasitic causes of cancers are well
recognised [15,16]. Immunosuppression in the absence of cancer
surveillance contributes to carcinogenesis [13].
3.1. Inﬂuence of more than one agent in cancer
causation
Additive or synergistic inﬂuence of two or more agents may
lead to cancer and is known as co-carcinogenesis [17]. Human
papilloma viruses, cervical tar exposures and fumes by coal or
wood-burning stoves causing cervical cancer is an example of
such synergy [18].
3.2. Suppression of cellular immunity and the link to
cancers
Suppression of cell mediated immunity predisposes to infec-
tious cancers [13], including Kaposi's sarcoma-associated herpes-
virus-linked lymphomas, Kaposi's sarcoma-associated herpesvirussarcomas, Ebstein-Barr virus, human papilloma viruses, head and
neck and cervical carcinomas and Merkel cell carcinomas [13,19].
HIV is an indirect carcinogen and HIV-induced immunosup-
pression promotes the development of tumours [20].
3.3. Early exposures, nutritional inﬂuences and speciﬁc
cancers
Early exposures could initiate carcinogenesis and subsequent
infections can trigger cancers [21]. Micronutrient deﬁciencies
contribute to squamous cell oesophageal cancer and the
potential prevention, through dietary diversiﬁcation and
increased consumption of rich sources of selenium and zinc
have been proposed in endemic areas [22]. Obesity predisposes
to cancers of the urogenital tract, gastrointestinal tract, liver,
endometrium and breast [23].
3.4. Some dietary genotoxins and their links to cancers
Dietary genotoxins are carcinogens in cooked food, some
plants and mushrooms, fungal products, nitrites, polycyclic ar-
omatic hydrocarbons and oxidative agents [24–26]. Heterocyclic
amines are associated with breast, colonic and prostatic
cancers [25,26].
3.5. The association of cancer to some drugs and
hormones
Drugs and hormones may have a role too. Sex hormones,
implicated in gene expression could lead to carcinogenesis of the
head and neck [27].
3.6. Lifestyle factors and cumulative exposures in cancer
causation
Lifestyle factors contribute to the global cancer incidence and
estimates from the World Health Organization and the Interna-
tional Agency for Research on Cancer are that toxic environ-
mental exposures contribute about 7%–19% to cancers [28]. The
cumulative effects of non-carcinogenic chemicals could act via
different mechanisms affecting organ systems, tissues and cells
to produce cancers [28].
4. Breastmilk cancer protection
As an effective anticancer tool, breastmilk must incorporate
overt or covert mechanisms as well as speciﬁc and nonspeciﬁc
means to destroy cancer cells. Nonspeciﬁcally, it must promote
an environment not conducive for the establishment of tumours
by reducing or counteracting the multifactorial causes of can-
cers, remove early tumour nidus and provide a milieu that does
not encourage tumour progression and metastases. A central
antitumour mechanism is apoptosis or programmed cell death
[29]. Directly, ideal antitumour action must promote apoptosis in
tumours and spare normal cells. As an anticancer tool,
breastmilk must also have the potential to overcome
mechanisms deployed by tumours to evade the immune
system. Additionally, anticancer action must include the
capacity to decrease or eliminate tumour predisposition and
improve innate immunity of surrounding tissue so that
apoptotic cells are removed and normal cells continue to thrive.
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by “bio-geno-immuno-nutrition”
Innate immunity in breastmilk provides substrates for much
effective anticancer functions. Lactoferrin and its peptide lac-
toferricin are breastmilk proteins with anti-infective, anti-
oxidant, immunomodulatory, and anti-inﬂammatory activities
[30,31], which in a broad sense, are anticancer actions.
From maternal plasma, innate immunity, via the milk fat
globule contains multifunctional mucins [32,33]. Puriﬁed
breastmilk mucin, MUC1 and MUC4, blocks infection by HIV
[32], which is associated with immunosuppression. Both
MUC1 and MUC4 block infection by Salmonella enterica
serovar typhimurium [33], Salmonella, a bacterial species
linked to cancers [15].
Dendritic cell-speciﬁc intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN), in the gastrointestinal tract
of the infant binds to MUC1 in breastmilk and protects via
Lewis x-type oligosaccharides, a response found only in
breastfed infants [34]. In fact, it is postulated that the infant
immune system is “shaped” by DC-SIGN [34]. Strengthened
mucosal immunity, augmented intestinal barriers and proper
immune maturation are anti-infective in the short term but also
shield from chronic inﬂammation in the long term. Chronic
inﬂammation promotes tumour growth, progression, and meta-
static spread [35].
Innate and adaptive immunity cooperate to optimise anti-
cancer function. Fatty acids regulate immunity linking intra-
luminal exposures, maternal nutrition and microbes [36], a triad,
when nurture is cancer protective. For the mother, in vitro
docosahexaenoic acid, a ligand of peroxisome proliferator-
activated receptors, is able to modulate peroxisome proliferator-
activated receptorb mRNA expression inhibiting mammary
tumour growth [37]. Substantial amounts of u-3 and u-6 long-
chain polyunsaturated fatty acids in breastmilk suppress the
production of tumour necrosis factor-a and may suppress auto-
immune disease and suggestion is that it may also prevent DNA
damage and remove emerging tumour cells [38]. Milk fat is the
most highly variable macronutrient of milk with high contents
of palmitic and oleic acids [31]. About 25% of the variation in
lipid concentration between mothers' milk may be explained by
maternal protein intake [31,39]. As alluded to earlier, obesity
predisposes to some cancers. Leptin, an antiobesity hormone in
breastmilk, was signiﬁcantly increased at night possibly
reﬂecting a 24 h pattern [40]. These observations emphasize the
counsel of uninterrupted and continuous breastfeeding in
enhancing its anticancer action.4.2. Breastfeeding and protection from early infections
In utero infection may trigger carcinogenesis [22], but this can
be modiﬁed by breastfeeding. Breastmilk has passive antibodies
due to maternal exposure and modulates immunity to postnatal
exposure [41]. Via uniﬁed immune communication between the
mother and the nursing infant through the enteromammary
axis, of which the lactating mammary gland is a part of,
secretory immunoglobulin A (sIgA) is produced [41,42],
protecting from early exposures to infections. Speciﬁc sIgA
from B cells confer speciﬁc protection without inﬂammation
[41,42]. A cytokine, interleukin 21 drives B cells to differentiate
to IgA+ cells and with transforming growth factor b1, augmentIgA class switch recombination [43]. At the cellular level, micro
RNAs (miRNAs) in breastmilk, play a role in innate immunity.
miRNAs are involved in the development of B cells and B cell
subsets differently express miRNA proﬁles [44]. miRNA has
a pivotal role in B cell maturation and if this is disrupted,
malignant transformation could occur [44]. Speciﬁc antibodies
against Shigella and Salmonella lipopolysaccharides in
colostrum and breastmilk are mainly IgA [41]. Exclusive
breastfeeding decreases Helicobacter pylori (H. pylori)
colonization, postpones infection and shortens duration of
symptoms [45]. Inadequately resolved chronic inﬂammation due
to H. pylori causing chronic gastritis may increase the risk of
cancer [46]; hence, H. pylori protection by breastmilk may be
recognised as an anticancer event.
4.3. Chronic parasitosis, carcinogenesis and the beneﬁts
of breastfeeding
Chronic parasitosis is linked to carcinogenesis [16]; parasite-
induced immunodeﬁciency and chronic inﬂammation contribute.
Inﬂammation provides bioactive substances for a sustainable
tumour microenvironment [46]. Epithelial mesenchymal transition,
can initiate cancer progression and is enhanced by proangiogenic
factors and metalloproteinases in chronic inﬂammation [46,47].
Inﬂammation also promotes genomic instability and immune
evasion [46,47]. Breastmilk has the potential to counteract parasite
pathogenicity as it has substances that reduce inﬂammation, and
factors that are antiparasitic with nonspeciﬁc and speciﬁc
function [31,48]. B and T cell maturation factors, antiprotozoal
action of fatty acids and sIgA protect against protozoan parasites
[31,48].
4.4. Viral factors, carcinogenesis and the recognised
advantages of breastfeeding
Viral spread and pathogenesis can lead to carcinogenesis [13].
Viral spread is restricted by extracellular vesicles, exosomes in
breastmilk [49]. Antiviral interferons and interferon-stimulated
genes with inﬂammatory cytokines stimulate adaptive immunity
to prevent virus induced pathogenesis [50,51]. It is now well
recognised that the immunological powerhouse by exclusive
breastfeeding through both innate and adaptive immunity have
impressive broad-based and speciﬁc antiviral action [11,31,32,42,49].
4.5. Breastfeeding as an integrated system against
oxygen free radicals (OFRs) and tumorigenicity
OFRs are tumorigenic, and affect the bases and the DNA
backbone [52]. Inﬂammation is also linked to reactive oxygen
and nitrogen species [53]. Enzymatic and non-enzymatic anti-
oxidant components, vitamins E and C, retinol, b-carotene,
lactoferrin, glutathione, catalase, superoxide dismutase and
glutathione peroxidase are in breastmilk, hence it is evident that
breastfeeding provides an integrated system against multifacto-
rial causes of OFRs [54].
It is important to note that the antioxidant potential in
breastmilk is more efﬁcient than infant formula and bovine milk
[55]. The total antioxidant capacity of breastmilk may be
inﬂuenced by diet, ethnicity or race [56]. Refrigeration and
freezing of breastmilk reduces individual antioxidants [56,57],
practical points in counseling for working mothers.
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Some factors in breastmilk have more direct antineoplastic
action [58,59]. Some have been used in the treatment of benign
and malignant growths [58,59].
4.7. Human alpha-lactalbumin made lethal to tumor
cells (HAMLET) in breastmilk
Partial digestion of its bionutrients has important anticancer
action. The pH of the gastric acid in the infant stomach may
trigger the change of the native whey protein to HAMLET [60].
Conﬁgurational changes of partial unfolding of alpha-
lactalbumin and binding to oleic acid with calcium release be-
stows it selective anticancer action [60]. HAMLET therapy
delays tumour progression without evidence of cell death in
healthy brain tissue [61]; topically, it removes skin papillomas
[58]. Local instillation in bladder cancer efﬁciently kills tumour
cells without much toxicity [59].
HAMLET binds to sensitive cells and accumulates in the
nucleus to initiate apoptosis whereas resistant cells do not show
intracellular localization of the active complex [59,60]. HAMLET
causes an ion channel-dependent response to kill cancer cells
[62]. For tumour surveillance, it reduces possible tumour nidus
[59,60] and initiates innate immune responses of normal cells,
providing an immune environment for elimination of apoptotic
cancer cells [59,60]. Through HAMLET-induced apoptosis,
potentially malignant cells that may function as nuclei for the
development of tumours are reduced explaining the decreased
frequency of cancer in those who are breastfed [60].
The breastfeeding child ingests around 2 g of a-lactalbumin
abundant in breastmilk, which travels from the mammary gland
through the gastrointestinal tract of the suckling child [60].
Through lactose, the water content of milk is controlled [60].
Milk from lactating mothers vary in the levels of medium-
chain and trans fatty acid partly dependant on diet [63]. Oleic
acid is a monounsaturated omega-9 fatty acid and the active
part of HAMLET [59,60]; hence, attention to maternal diet or diet
supplementation may potentially enhance the quality of
breastmilk anticancer function.
4.8. TNF-related apoptosis inducing ligand (TRAIL) in
breastmilk
Tumours evade apoptosis [29]. Direct anticancer action must
deal effectively with it. TRAIL, is a cytokine abundant in
colostrum [64]. TRAIL binds to surface receptors of the tumour
necrosis factor receptor superfamily, TRAIL-R1 (DR4), TRAIL-
R2 (DR5), TRAIL-R3 (DcR1), and TRAIL-R4 (DcR2) [65–67].
TRAIL-R1 and TRAIL-R2 contain the death domain and induce
apoptosis [65]. TRAIL-R3 and TRAIL-R4 are capable of apoptotic
signalling and have decoy function [65,66]. miRNAs in breastmilk
regulate apoptosis through targeting oncogenes or tumour
suppressor genes [67], via extrinsic and intrinsic pathways [67,68].
The extrinsic pathway involves the death receptor family with
death domains as Fas, TRAIL-R1 (DR4), TRAIL-R2 (DR5) or
TNF-R1 [69]. Multiple myeloma cells are sensitive to TRAIL-
mediated apoptosis [69]. It is plausible that TRAIL in breastmilk
is efﬁcient in apoptosis via the extrinsic pathway. Decoy
receptors for TRAIL could block TRAIL-mediated apoptosis
[70]. In vitro, TRAIL is up-regulated during morphogenesis ofMCF-10A mammary epithelial cells [71]. Milk osteoprotegerin,
possibly from milk cells and the human mammary epithelial cell
line, may contribute to TRAIL-induced inhibition of T cell
proliferation [72], enhancing apoptosis by TRAIL.
The intrinsic apoptotic pathway leads to mitochondrial per-
meabilization of outer membranes and release of apoptogenic
proteins into the cytosol [73]. This is controlled by the Bcl-2
family members [73,74]. Mammary gland tissue, expresses a
number of different Bcl-2 relatives including bcl-x, bax, bak,
bad, bcl-w, bﬂ-1, bcl-2 as well as the bcl-2 binding protein Bag-
1 [74]. Lactaptin, from human milk kappa-casein, suppresses
Bcl-2 mRNA expression and downregulates Bcl-2 protein
expression [75]. Recombinant lactaptin penetrates cancers and
suppresses growth of solid tumours [75]. There is suggestion
that milk directly affects epigenetic changes [76]; hence given
the role of milk kappa-casein on Bcl-2, could breastfeeding
potentially inﬂuence genes of the Bcl-2 family proteins to
modulate the intrinsic apoptotic pathway? If so, are there
mother-to-infant signals for this in speciﬁc situations? This is not
too far fetched as high levels of TRAIL are maintained in the
milk of mothers who deliver prematurely [77]. Gene expression
by miRNA is signiﬁcant as a single miRNA can inﬂuence
many genes [78]. Additionally, milk-derived exosomal miR-
NAs may control thymic T regulatory cell maturation [79]. The
variable numbers of these micro-nucleotides in the mammary
gland, in colostrum and mature milk [78], reﬂect vibrant gene
expression during breastfeeding.
Breastmilk lactoferrin, a possible biomarker for illnesses [80],
regulates apoptosis related genes and G1 cyclin-dependent ki-
nases causing cell cycle arrest, targeting for anticancer therapy
[81]. It is appreciated that within breastmilk lies cancer
immunoprophylaxis and immunotherapy. Lactoferrin may be
regulated by nutrition, growth and transcriptional factors and
nuclear receptors [81]. At cellular levels, miR214 may inﬂuence
lactoferrin expression and proapoptosis in mammary epithelial
cells [82]. Psychological stresses can inﬂuence biological milieu
[83]; this in turn can be postulated to possibly affect miRNA
mediated processes at the cellular level contributing to
anticancer action. If this were true, modiﬁable factors such as
the well being of the mother are deemed essential to nurture for
protection from cancers through breastfeeding.4.9. Mother-to-infant communication
Biocommunication from mother-to-infant through milk
microvesicles transfer genetic signals during breastfeeding [84].
Maternal genomic information incorporated into cells of the
suckling infant may explain tolerance to maternal allografts in
breastfed children [84]. Speculation is that RNA from a healthy
wet-nurse through milk microvesicles and incorporation into
the genome could even cure clinical manifestations in genetic
diseases [84]. Integrated responses of maternal RNA with turnover
of intestinal cells and intestinal microbiome to dietary substrates
in the neonatal period, indicate that even donor milk, where
pasteurization kills its bacterial inoculum from maternal gut,
would be imperfect, such milk devoid of dynamic integration
[84]. Furthermore, differences in expressed genes among
breastfed and bottle fed infants stress the key role of dynamic
bioactive breastmilk components with “more intense
bimolecular cross talk” and a “co-expression of more genes” in
the breast-fed [42]. What else activates “biosignaling”? Perhaps
Prameela Kannan Kutty/Asian Pac J Trop Biomed 2016; 6(5): 422–428426initiated within the mammary epithelial cell, what is the impact of
their function in protection? Much in-depth study needs to be
done to throw more light on these events.
5. Discussion
Anticancer potential in breastmilk must be both understood
and realised. The many probable causes of cancers necessitate
unique, multipronged protection that preempts danger dynami-
cally to “warning signals” for cancer causation, selectively clears
cancer nidus and improves immunity of tissues that are nearby.
As suggested in this review, such conviction is reasonably
present in exclusive breastfeeding. Impossible to entirely
emulate by cancer therapy or by speciﬁc incorporation into
artiﬁcial formula, its cost effectiveness, absence of side effects
and prized investment simply in maternal health and education
are important to reiterate.
The anticancer protection by breastfeeding is possibly
contributed to by maternal factors, factors affecting the breast-
feeding process and “bio-geno-immuno-nutrition” alluded in this
article that are within breastmilk (Figure 1).
It is hypothesised that nutrition and psychosocial issues may
inﬂuence its potential. Cumulative duration of breastfeeding and
the length of an individual feed may also be pivotal. Mothers of
term infants are advised to exclusively breastfeed and to empty
an entire breast prior to feeding from the other breast as hindmilk
is more energy dense due to its higher lipid content [31,56]. It is
useful to remember that the interactive interdependence of multi-
nutrients in vivo [31,56], and its possible contribution to
anticancer action, providing a window of opportunity to
eradicate macro and micronutrient malnutrition globally.
Empowered with this knowledge of breastmilk protection,
global rates of exclusive breastfeeding would improve signiﬁ-
cantly because every mother would want to protect her child from
cancers. Speciﬁcally, in communities where carcinogenic toxins
are known to be present at high levels or amongst individuals
who are predisposed to higher cancer risks, extensive community
and meticulous individual counsel of exclusive and prolonged
breastfeeding may well be deemed essential for survival.Maternal factors and 
factors affecting the 
process of breastfeeding
Breastmilk factors
More direct action by 
TRAIL, lactoferrin, 
HAMLET, LCPUFAs
Breastmilk factors
Mainly indirect action 
by proteins, fatty acids, 
immunological, boi-
nutritional and genetic 
factors including nucleotides 
such as miRNA
Figure 1. Hypothesis on anticancer protection of breastfeeding.
LCPUFAs: Long-chain polyunsaturated fatty acids.Conﬂict of interest statement
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